Introduction {#s1}
============

*Clostridioides difficile* is a gram-positive bacterium that was initially thought to be benign and isolated from the fecal flora of healthy newborns \[[@R01]\]. Bartlet \[[@R02]\] described its association with pseudomembranous colitis, and by the late 1980s, his team described multiple aspects of this illness. In the USA, *Clostridioides difficile* infection (CDI) is a common healthcare-associated infection (HCAI). The incidence of CDI has increased dramatically over the past two decades \[[@R03]\]. Multiple CDI outbreaks in acute care facilities have been attributed to the North American pulsed-field gel electrophoresis type 1 (NAP1) strain \[[@R04], [@R05]\]. Broad-spectrum antibiotics, prolonged hospitalization, advanced age, renal insufficiency, multiple comorbidities, immunosuppression, use of proton pump inhibitors (PPIs), and hypoalbuminemia are some of the widely recognized risk factors for CDI \[[@R04], [@R06]-[@R08]\].

Patients with liver cirrhosis have poor immunity, weaker immune response during illness, and a propensity for increased bacterial translocation and endotoxemia \[[@R9]\]. CDI is an independent mortality risk factor in patients with chronic liver disease similar to hepatic encephalopathy, spontaneous bacterial peritonitis and variceal bleeding \[[@R10]\]. Patients with liver cirrhosis and concurrent CDI have worse outcomes when compared to those without CDI. We conducted this study to assess the outcomes of CDI in patients with and without liver cirrhosis between 2012 and 2015.

Materials and Methods {#s2}
=====================

Data source {#s2a}
-----------

The National Inpatient Sample (NIS) database is one of the largest inpatient databases that includes more than 4,000 hospitals and an estimated average of eight million admissions annually. It provides a large number of clinical and nonclinical variables from many hospitals that can be utilized to estimate outcomes for various clinical conditions and patient populations \[[@R11]\].

Study design {#s2b}
------------

We used the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) to select our study population. Patients admitted with CDI as a primary or secondary diagnosis were identified using ICD-9-CM code 008.45. Only patients who were admitted between January 2012 and September 2015 were included in the study as the administrative data for hospitals started implementing ICD-10-CM in October 2015. Patients with a history of liver cirrhosis were identified using the ICD-9-CM codes 571.2, 571.6 and 571.5 ([Fig. 1](#F1){ref-type="fig"}). We looked at the in-hospital mortality, length of stay (LOS), and hospitalization as the final outcomes. We also collected demographic information in addition to other comorbid conditions and risk factors.
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Statistical analysis {#s2c}
--------------------

NIS database was analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Continuous variables were described in the form of means ± standard deviations (SDs). Chi-square test and Student's *t*-test were utilized to analyze categorical and continuous variables, respectively. Adjusted in-hospital mortality was calculated by multivariate logistic regression analysis. Patient variables, hospital characteristics, and comorbid conditions were analyzed using multivariate models. Statistical significance was set at a two-sided value of P \< 0.05.

Results {#s3}
=======

A total of 1,327,595 patients with CDI were hospitalized between January 2012 and September 2015. Of them, 3.97% (52,765) had a history of concurrent liver cirrhosis. The mean age for patients with liver cirrhosis was 60 years compared to 67 years for those without a history of liver cirrhosis. Most of our patients were Caucasians (71%) and women (58%). Diabetes mellitus, alcohol abuse, acquired immunodeficiency, and solid tumors were noted significantly more in patients with liver cirrhosis. Patients with cirrhosis were more likely to be admitted to large urban teaching hospitals (66.1% vs. 58.2%, P \< 0.001) and to have private insurance (19.5% vs. 17.6%, P \< 0.001). The inpatient mortality was higher in patients with CDI and cirrhosis (10.1% vs. 6.9%, P \< 0.001). The LOS (11 days vs. 10.4 days) and cost (23,055 vs. 26,535) were also significantly different between the two groups after adjusted analysis ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

###### Baseline Characteristics of Index Hospitalizations Secondary to CDI

  Variables                                 No cirrhosis          Cirrhosis             Total               P value
  ----------------------------------------- --------------------- --------------------- ------------------- -----------
  Patient level variables                                                                                   
    Mean age                                67.4 ± 17.2           60.3 ± 12.8                               \< 0.001
    Gender                                                                                                  \< 0.0001
      Men                                   521,505 (41.0%)       28,900 (54.8%)        550,405 (41.5%)     
      Women                                 753,245 (59.0%)       23,865 (45.2%)        777,110 (58.5%)     
    Race                                                                                                    \< 0.0001
      White                                 909,590 (71.4%)       35,085 (66.5%)        944,675 (71.2%)     
      Black                                 157,500 (12.3%)       5,785 (11.0%)         163,285 (12.3%)     
      Others                                207,725 (16.3%)       11,890 (22.5%)        219,615 (16.5%)     
    Comorbidities                                                                                           
      Obesity                               145,400 (11.4%)       6,005 (11.4%)         151,405 (11.4%)     0.8606
      Congestive heart failure              255,360 (20.0%)       8,835 (16.7%)         264,195 (20.0%)     \< 0.0001
      History of hypertension               787,230 (61.8%)       27,350 (51.8%)        814,580 (61.4%)     \< 0.0001
      Diabetes                              280,525 (22.0%)       13,485 (25.6%)        294,010 (22.2%)     \< 0.0001
      Alcohol abuse                         48,320 (3.8%)         19,950 (37.8%)        68,270 (5.1%)       \< 0.0001
      Toxic megacolon                       1,925 (0.2%)          50 (0.1%)             1,975 (0.2%)        0.001
      Acquired immune deficiency syndrome   5,635 (0.4%)          535 (1.0%)            6,170 (0.5%)        \< 0.0001
      Metastatic cancer                     53,275 (4.2%)         1,165 (2.2%)          54,440 (4.1%)       \< 0.0001
      Solid tumor without metastasis        49,580 (3.9%)         2,520 (4.8%)          52,100 (4.0%)       \< 0.0001
      Renal failure                         332,890 (26.1%)       13,930 (26.4%)        346,820 (26.1%)     0.1406
      Chronic lung disease                  313,575 (24.6%)       12,305 (23.3%)        325,880 (24.6%)     \< 0.0001
    Primary payer                                                                                           \< 0.0001
      Medicare/medicaid                     992,350 (77.9%)       38,180 (72.4%)        1,030,530 (77.6%)   
      Private insurance                     224,575 (17.6%)       10,300 (19.5%)        234,875 (17.7%)     
      Self-pay/others                       57,615 (4.5%)         4,265 (8.1%)          61,880 (4.7%)       
  Hospital characteristics                                                                                  
    Hospital bed size                                                                                       \< 0.0001
      Small                                 193,270 (15.2%)       6,770 (12.8%)         200,040 (15.1%)     
      Medium                                344,310 (27.0%)       14,080 (26.7%)        358,390 (27.0%)     
      Large                                 737,250 (57.8%)       31,915 (60.5%)        769,165 (57.9%)     
    Hospital location/teaching status                                                                       \< 0.0001
      Rural                                 115,830 (9.1%)        2,995 (5.7%)          118,825 (9.0%)      
      Urban nonteaching                     416,975 (32.7%)       14,905 (28.3%)        431,880 (32.5%)     
      Urban teaching                        742,025 (58.2%)       34,865 (66.1%)        776,890 (58.5%)     
    Disposition                                                                                             \< 0.0001
      Home                                  465,470 (36.5%)       20,885 (39.6%)        486,355 (36.7%)     
      Facility/others                       713,590 (56.0%)       25,855 (49.0%)        739,445 (55.7%)     
      AMA                                   7,040 (0.6%)          685 (1.3%)            7,725 (0.6%)        
      Died                                  88,190 (6.9%)         5,315 (10.1%)         93,505 (7.0%)       
    Cost                                                                                                    \< 0.001
      Mean                                  23,055.6 ± 39,926.9   26,535.3 ± 41,379.2                       
    Length of stay                                                                                          \< 0.001
      Mean                                  10.4 ± 13.2           11.0 ± 12.9                               

AMA: against medical advice; CDI: *Clostridioides difficile* infection.

###### Adjusted Mortality of CDI Admissions

  Outcomes (mortality)   Adjusted odds ratio   Lower limit   Upper limit   P value
  ---------------------- --------------------- ------------- ------------- -----------
  Without cirrhosis      Reference             Reference     Reference     Reference
  With cirrhosis         1.65                  1.53          1.77          \< 0.001

Adjusted with age, gender, hospital level characteristics (hospital type, bed-size) and comorbidities (obesity, congestive heart failure, hypertension, diabetes mellitus, metastatic cancer, immunodeficiency, alcohol abuse, toxic megacolon, renal failure, chronic lung disease). CDI: *Clostridioides difficile* infection.

Discussion {#s4}
==========

Almost 4% of all admitted patients with CDI had a history of liver cirrhosis. This is lower than the prevalence of liver cirrhosis in the general population (4.5% to 9.0%) \[[@R12]\]. The in-hospital mortality in patients was significantly higher in patients with CDI and liver cirrhosis when compared to the cohort without cirrhosis (odds ratio (OR) 1.65, 95% confidence interval (CI) 1.53 - 1.77, P \< 0.001) after adjusting for patient-level variables, comorbidities and hospital-level characteristics. We adjusted for alcohol abuse, immunodeficiency, toxic megacolon, metastatic cancer, congestive heart failure and chronic renal disease. Bajaj et al \[[@R10]\] demonstrated that mortality in patients with liver cirrhosis and CDI (13.8%) was significantly higher than in patients with cirrhosis (8.2%) or CDI (9.6%) alone. Rosenblatt et al \[[@R13]\] found CDI to be an independent risk factor for mortality in the same patient population. This could possibly be related to generalized suppression of defense mechanism associated with liver failure, effects of hypoalbuminemia and increased risk of bacterial translocation resulting in spontaneous bacterial peritonitis in patients with chronic liver disease.

Smith et al \[[@R14]\] reported prolonged LOS in patients with liver cirrhosis and CDI when compared to patients without CDI (15.1 days vs. 6.55 days). Bajaj et al \[[@R10]\] noted that LOS was as twice as long in patients with cirrhosis and CDI, compared to patients without CDI (14.4 days vs. 6.7 days). The length of hospital stay was prolonged for patients with CDI and liver cirrhosis as compared to those without cirrhosis but only by a minimal margin (11 days vs. 10.4 days). Although the difference was statistically significant, the effect of cirrhosis on the LOS for patients with CDI does not seem that remarkable as the effect of CDI on patients with cirrhosis. The reasons for the discrepancy in the observed results remain unclear and limited by the nature of the NIS database.

The cost associated with in-hospital stay was significantly higher in patients with cirrhosis than in those without among the entire cohort with CDI. Dotson et al \[[@R15]\] conducted a similar study on the same database from 2009 and found similar findings. This could be related to complications secondary to chronic liver disease that resulted in further diagnostic and therapeutic endoscopies, admission to the intensive care unit (ICU) and additional treatments. It is hard to tell how much of the cost could be attributed directly to the LOS since the difference between the two groups was not that remarkable when it came to LOS. Overall, the outcomes of CDI in patients with liver cirrhosis were worse when compared to patients without liver cirrhosis. The impact of liver cirrhosis on LOS in patients with CDI is not as notable as that of CDI in patients with liver cirrhosis.

Limitations {#s4a}
-----------

The study is limited by utilizing the discharge diagnoses and the billing codes of the NIS database that subject the data to inaccuracy related to under documentation and missing codes. There were significant differences in patient-level variables, hospital characteristics and comorbidities between the two groups at baseline. We aimed to limit the effect of difference at baseline by running a multivariate analysis, but this would not account for all possible confounding factors between the two groups. We could not assess the CDI severity, stage of liver cirrhosis, use of prophylactic antibiotic therapy, invasive and surgical interventions of our study sample.

Conclusions {#s4b}
-----------

To our knowledge, this is the largest study to date looking at the outcomes of CDI in patients with liver cirrhosis. Patients with CDI and liver cirrhosis have significantly higher mortality, prolonged hospitalization and healthcare expenditure. Further studies are recommended to look at reversible risk factors for CDI in patients with liver cirrhosis to guide quality measures that would ultimately improve outcomes.
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